THE IBN SINA PHARMACEUTICAL INDUSTRY PLC |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 249.2 BDT | +0.48% |
|
+0.61% | -13.05% |
| Sales 2024 * | 11.22B 95.3M | Sales 2025 * | 12.74B 108M | Capitalization | 7.79B 66.11M |
|---|---|---|---|---|---|
| Net income 2024 * | 712M 6.05M | Net income 2025 * | 813M 6.9M | EV / Sales 2024 * | 0.69 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.61 x |
| P/E ratio 2024 * |
10.9
x | P/E ratio 2025 * |
9.58
x | Employees | 4,000 |
| Yield 2024 * |
2.85% | Yield 2025 * |
3.25% | Free-Float | 55.32% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.48% | ||
| 1 week | +0.40% | ||
| Current month | -0.24% | ||
| 1 month | +6.40% | ||
| 3 months | -3.82% | ||
| 6 months | -13.05% | ||
| Current year | -13.05% |
1 week
240.20
251.70
1 month
234.20256.00
Current year
223.50286.60
1 year
223.50289.70
3 years
223.50348.00
5 years
192.00348.00
10 years
61.32348.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 69 | 02-12-31 | |
Chowdhury Hasan
DFI | Director of Finance/CFO | 70 | 12-12-31 |
Mohammad Uddin
DFI | Director of Finance/CFO | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 76 | 82-12-31 | |
Abdus Bhuiyan
BRD | Director/Board Member | 65 | 22-01-15 |
| Chief Executive Officer | 69 | 02-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-16 | 249.2 | +0.48% | 22,884 |
| 24-07-15 | 248 | -0.72% | 6,381 |
| 24-07-14 | 249.8 | +1.01% | 2,269 |
| 24-07-11 | 247.3 | -0.16% | 15,505 |
| 24-07-10 | 247.7 | -0.20% | 9,335 |
End-of-day quote Dhaka S.E., July 15, 2024
More quotes
The IBN SINA Pharmaceutical Industry Ltd is a Bangladesh-based pharmaceutical company. The Company is engaged in production, trading, and other related activities of Active Pharmaceutical Ingredients (API) and other related products. The Company offers its products under pharma and natural. Its products in a range of therapeutic class, such as Antibiotic, Anti-ulcerant, Antiasthmatic, Antihistamine, Cough Medicines, Antidiabetic, Antispasmodic, Antineuropathic, Cardiovascular drugs (CVS drugs), Central Nervous System (CNS drugs), Gastroprokinetic agent, NSAIDs (nonsteroidal anti-inflammatory drugs) and Laxative. In Antibiotics the Company is enriched in Penicillins with brands Sinamox, Sinaclox, Sinaflox, among others. In Anti-ulcerant portfolio having pioneer brands like Dexlan and Gavisol. Antiasthmatic drugs including Ventisal, Ventisal-L, Xofyl, Montex, among others. Antihistamine brands including Bilamin, Fexomin, Rupamin, Ebamin, Sinamin, Nosemin, Silora, among others.
Sector
Pharmaceuticals
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
249.2
BDT
Average target price
390
BDT
Spread / Average Target
+56.50%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -13.05% | 66.07M | |
| +25.40% | 45.35B | |
| +38.38% | 24.34B | |
| +27.09% | 16.51B | |
| +21.19% | 14.6B | |
| +71.91% | 14.27B | |
| -0.05% | 6.79B | |
| -11.63% | 6.57B | |
| +13.07% | 5.76B | |
| -8.87% | 5.73B |
- Stock Market
- Equities
- IBNSINA Stock
